Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead

Revenues up 18% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead

4Q Revenues: $2.6 billion (+18%)

4Q Earnings: $759.0 million (+15%)

FY Revenues: $9.7 billion (+16%)

FY Earnings: $2.6 billion (-8%)

Comments: Growth in the quarter was driven by the antiviral franchise. Complera/Eviplera sales were $117.8 million compared to $19.7 million in 4Q11.  Atripla sales were up 6% to $917.5 million and Truvada sales were up 12% to $832.7 million. Sales of Viread were up 19% to $226.7 million. Cardiovascular product sales were up 33% to $215.2 million. Sales of other products, including AmBisome and Cayston, increased 15% to $127.7 million. Royalty, contract and other revenues from collaborations were $77.5 million in the quarter, up 16%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters